Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
J Clin Med. 2016 Feb 3;5(2):20. doi: 10.3390/jcm5020020.
The Protein Kinase D (PKD) isoforms PKD1, PKD2, and PKD3 are effectors of the novel Protein Kinase Cs (nPKCs) and diacylglycerol (DAG). PKDs impact diverse biological processes like protein transport, cell migration, proliferation, epithelial to mesenchymal transition (EMT) and apoptosis. PKDs however, have distinct effects on these functions. While PKD1 blocks EMT and cell migration, PKD2 and PKD3 tend to drive both processes. Given the importance of EMT and cell migration to the initiation and progression of various malignancies, abnormal expression of PKDs has been reported in multiple types of cancers, including breast, pancreatic and prostate cancer. In this review, we discuss how EMT and cell migration are regulated by PKD isoforms and the significance of this regulation in the context of cancer development.
蛋白激酶 D(PKD)同工型 PKD1、PKD2 和 PKD3 是新型蛋白激酶 C(nPKC)和二酰基甘油(DAG)的效应物。PKD 影响多种生物过程,如蛋白质运输、细胞迁移、增殖、上皮间质转化(EMT)和细胞凋亡。然而,PKD 在这些功能上具有不同的作用。PKD1 阻止 EMT 和细胞迁移,而 PKD2 和 PKD3 则倾向于促进这两个过程。鉴于 EMT 和细胞迁移对各种恶性肿瘤的发生和发展的重要性,PKD 在多种类型的癌症中,包括乳腺癌、胰腺癌和前列腺癌中的表达异常已有报道。在这篇综述中,我们讨论了 EMT 和细胞迁移是如何被 PKD 同工型调节的,以及这种调节在癌症发展中的意义。